This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ACZ885 administered via intravenous infusion and subcutaneous injection in healthy Japanese male volunteers.

Inclusion Criteria:

• Japanese healthy male subjects age 20 to 45 years of age, and in good health
• At screening and baseline, the subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis.
• Body mass index within the range of 18 to 28 kg/m2 and weigh 50 to 100 kg

Exclusion Criteria:

• Smokers.

• Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing. Acetaminophen is acceptable. Treatment of any biologics within three months prior to dosing. Having live vaccinations within six months prior to dosing.

• Participation in any clinical investigation within 4 months prior to dosing.

• Donation or loss of 400 mL or more of blood within 3 months; donation or loss of 200 mL or more of blood within 1 month; or donation of component blood within 2 weeks prior to participation.

• Significant illness (sinusitis, pneumonia, cystitis, sepsis, etc) within two weeks prior to dosing.

• A past personal or close family medical history of cardiac disorders

• History of:

  • fainting,
  • low blood pressure when standing,
  • abnormal heart rhythms
  • acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).

• Clinically significant drug allergy or history and complication of atopic allergy (asthma, urticaria, eczematous dermatitis)

• Known hypersensitivity to the study drug or similar drugs

• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or jeopardize participation in the study.

• History of immunodeficiency diseases, including a positive HIV test result.

• A positive Hepatitis B surface antigen (HBsAg), Hepatitis C or Syphilis test result.

• Drug or alcohol abuse within the 12 months prior to dosing

• Tuberculosis symptoms, complication of tuberculosis, contact with patients with suspected tuberculosis symptoms

Other protocol-defined inclusion/exclusion criteria may apply